Skip to main content
. 2011 Sep;6(9):2185–2191. doi: 10.2215/CJN.03140411

Figure 3.

Figure 3.

Soluble CD40L (sCD40L) in patients with atherosclerotic renal artery stenosis randomly assigned to either abciximab or Angioguard embolic protection, both, or neither. Data presented as mean ± SEM, *P = 0.003 versus baseline, **P = 0.002 versus baseline, #P = 0.03 versus baseline.